Search / Trial NCT00002084

A Comparative Trial of Valacyclovir Hydrochloride ( 256U87 ) and Acyclovir for the Suppression of Anogenital Herpes Infections in HIV-Infected Patients

Launched by GLAXO WELLCOME · Aug 30, 2001

Trial Information

Current as of December 26, 2024

Completed

Keywords

Acyclovir Acquired Immunodeficiency Syndrome Aids Related Complex Antiviral Agents Anus Diseases Herpes Genitalis

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria
  • Patients must have:
  • HIV infection with CD4 counts = or \> 100 cells/mm3.
  • Documented culture of anogenital herpes simplex virus (HSV) within the last 5 years.
  • History of recurrent anogenital HSV infection, with a recurrence (with or without culture) within 1 year prior to study.
  • Exclusion Criteria
  • Co-existing Condition:
  • Patients with the following symptoms and conditions are excluded:
  • Malabsorption or vomiting that would potentially limit the retention and absorption of oral therapy.
  • Concurrent Medication:
  • Excluded:
  • Systemic antiherpes medication.
  • Interferon.
  • Patients with the following prior conditions are excluded:
  • History of hypersensitivity to acyclovir.

About Glaxo Wellcome

Glaxo Wellcome, a leading global biopharmaceutical company, is dedicated to advancing healthcare through innovative research and development of new therapies. With a strong focus on addressing unmet medical needs, Glaxo Wellcome combines scientific excellence with a commitment to improving patient outcomes across various therapeutic areas, including respiratory, infectious diseases, and oncology. The company is recognized for its robust clinical trial portfolio, leveraging cutting-edge technology and collaborative partnerships to drive the development of transformative treatments. Glaxo Wellcome upholds the highest ethical standards in clinical research, ensuring patient safety and integrity throughout the trial process.

Locations

Houston, Texas, United States

Los Angeles, California, United States

New York, New York, United States

New York, New York, United States

Chicago, Illinois, United States

Washington, District Of Columbia, United States

Atlanta, Georgia, United States

Washington, District Of Columbia, United States

San Francisco, California, United States

San Francisco, California, United States

New York, New York, United States

Philadelphia, Pennsylvania, United States

Memphis, Tennessee, United States

Washington, District Of Columbia, United States

Washington, District Of Columbia, United States

Wichita, Kansas, United States

Galveston, Texas, United States

Atlanta, Georgia, United States

Portland, Oregon, United States

Baltimore, Maryland, United States

Rochester, New York, United States

Mobile, Alabama, United States

Tucson, Arizona, United States

St. Paul, Minnesota, United States

San Francisco, California, United States

Indianapolis, Indiana, United States

Orange, California, United States

West Haven, Connecticut, United States

Chicago, Illinois, United States

Jackson, Mississippi, United States

Providence, Rhode Island, United States

Kansas City, Missouri, United States

Richmond, Virginia, United States

San Diego, California, United States

Los Angeles, California, United States

Oakland, California, United States

San Diego, California, United States

St. Petersburg, Florida, United States

Iowa City, Iowa, United States

St. Louis, Missouri, United States

Pittsburgh, Pennsylvania, United States

Dallas, Texas, United States

Houston, Texas, United States

Houston, Texas, United States

Houston, Texas, United States

Nassau Bay, Texas, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials